Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved - Deletion of the viral E1b-19-kD gene increases the viral oncolytic effect

Human Gene Therapy

Volumn 12, Issue 10, 2001, Pages 1323-1332

  Harrison, D ^a   Sauthoff, H ^a   Heitner, S ^a   Jagirdar, J ^a   Rom, W N ^a   Hay, J G ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AD 309; AD 337; ONCOLYTIC VIRUS; RECOMBINANT DNA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONNECTIVE TISSUE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GENE DELETION; GENE THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PERSISTENT VIRUS INFECTION; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; VIRUS GENE; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS TITRATION;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ANIMALS; CELL DIVISION; GENE DELETION; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; TIME FACTORS; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS; RNA VIRUSES;

EID: 0034917855     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303401750270977     Document Type: Article

References (53)

1. Blood clearance rates of adenovirus type 5 in mice
2. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
3. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
4. The development of conditionally replicative adenoviruses for cancer therapy
5. Conditionally replicative adenoviruses for cancer therapy
6. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions
7. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein
8. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
9. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
10. Productive replication of human adenoviruses in mouse epidermal cells
11. Methods for construction of adenovirus vectors
12. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma
13. The hallmarks of cancer
14. p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication
15. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs
16. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus
17. Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector
18. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells - The importance of the adenoviral E1b-55kD gene
19. Replication-selective adenoviruses as oncolytic agents
20. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects
21. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
22. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors
23. Delivery of molecular and cellular medicine to solid tumors
24. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins
25. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
26. The interaction between host-supplied connective tissue and xenografted human tumor cells
27. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen
28. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience)
29. p53, the cellular gatekeeper for growth and division
30. Adenovirus E1B 55K represses p53 activation in vitro
31. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy
32. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial
33. Virology in the next millennium
34. Tumor-suppressor p53 and the cell cycle
35. Deletion of the gene encoding the adenovirus 5 early region 1b 21,000-molecular-weight polypeptide leads to degradation of viral and host cell DNA
36. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015)
37. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
38. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F
39. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium
40. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
41. Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector
42. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer
43. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
44. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
45. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status
46. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment
47. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: Assessment of antitumor efficacy and toxicity
48. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer
49. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ
50. Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract
51. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration